Current Cardiology Reports

, Volume 11, Issue 5, pp 323–324

Prasugrel versus clopidogrel in primary PCI: Considerations of the TRITON-TIMI 38 substudy

Clinical Trials Report

References

  1. 1.
    Antman EM, Hand M, Armstrong PW, et al.: 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008, 51:210–247.PubMedCrossRefGoogle Scholar
  2. 2.
    Van de Werf F, Bax J, Betriu A, et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008, 29:2909–2945.PubMedCrossRefGoogle Scholar
  3. 3.
    Mega JL, Close SL, Wiviott SD, et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354–362.PubMedCrossRefGoogle Scholar
  4. 4.
    Aubert R, Epstein R, Teagarden J, et al.: Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Presented at the 2008 American Heart Association Scientific Sessions. New Orleans, LA; November 8–12, 2008.Google Scholar
  5. 5.
    Kastrati A, Mehilli J, Neumann FJ, et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006, 295:1531–1538.PubMedCrossRefGoogle Scholar
  6. 6.
    Wiviott SD, Trenk D, Frelinger AL, et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923–2932.PubMedCrossRefGoogle Scholar
  7. 7.
    De Luca G, Suryapranata H, Stone GW, et al.: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005, 293:1759–1765.PubMedCrossRefGoogle Scholar
  8. 8.
    Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001–2015.PubMedCrossRefGoogle Scholar
  9. 9.
    Jakubowski JA, Winters KJ, Naganuma H, Wallentin L: Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007, 25:357–374.PubMedCrossRefGoogle Scholar
  10. 10.
    Kastrati A, Mehilli J, Schuhlen H, et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004, 350:232–238.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.LexingtonUSA

Personalised recommendations